Method of treating conjunctiva nevus

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology and concerns treating conjunctiva nevus. That is ensured by administration of tabletted or capsulated chitosan in a dose 125-300 mg 2-3 times a day within a month.

EFFECT: method provides effective treatment of the disease without surgical intervention.

4 ex

 

The invention relates to medicine, specifically to ophthalmology, and can be used for the treatment and prevention of nevi of the conjunctiva of the eye.

Nevus is a benign tumor of the conjunctiva of the eye. Developing people in a stressful situation, when consumed substances-antioxidants in large quantities and not crumbling from food or drugs. Antioxidants - cleaners of the body, they removed continuously formed negative cells, which are formed tumors.

Currently, the treatment of nevus is radical removal by surgical excision.

There is a method of treatment of nevus, which in accordance with EN 2277880 perform laser infrared thermotherapy with a wavelength of 810 nm, the radiation power 1200-1370 mW and a spot diameter at the focal plane of 2-3 mm, exposure radiation 60 seconds, the number of pulses 5. Exposure is performed by overlapping the affected area tiled 1-2 times.

This method aims to reduce the morbidity of the operation, the extent of the surgery and the reduction of treatment time.

However, this method is still surgical and requires special equipment.

The objective of the invention is to provide a therapeutic method for the treatment of nevus.

Task resets the treatment of nevus of the conjunctiva of the eye through the introduction of chitosan at a dose of 125-300 mg in the form of tablets or capsules 2-3 times a day for months.

Chitosan is a natural product made from the tanks of crabs by removing acyl, which gives rigidity chitin. The purified chitin "chitosan", is an ion with a positive charge and a high degree of activity, which depends on the degree of purification of chitin by atsetilirovaniya. The higher the degree of removal of the acyl is, the higher the functional effect of this product.

Chitosan is a functional product health properties. It slows the aging process, strengthens the immune system, is a good means of prevention.

The method is as follows.

The author found that regular use of chitosan rate 1-3 tablets (capsule) (125-300 mg of chitosan, but not less than 100 mg for 1 admission) 2-3 times a day for months leads to resorption of nevi of the conjunctiva of the eye. The tablets should be taken one hour after food and drink 1/2 Cup lukewarm or cold water. Do not take with other medications, as chitosan lead them out of the body.

In the future, it is advisable to carry out prevention 2 times per year from 15 March to 15 April and 15 October to 15 November, which consists in taking vitamins-antioxidants (for example, aevit), iodine preparations (for example, say or ioactive) and ascorbic acid.

The author treated predlozhennym way 60 patients, had nevus. The good result of treatment, patients cured completely.

An example of treatment 1.

Patient N., 53 years old, I went to the doctor about nevus on the mucous membrane of the right eyeball. Was prescribed treatment with chitosan. After a course of reception of chitosan 1 capsule (200 mg) 3 times a day for months nevus is completely resorbed. Scheduled preventive intake of vitamins (aevit and ascorbic acid) and say 2 times a year in spring and autumn in the month.

An example of treatment 2.

Patient G., 46 years old, I went to the doctor about nevus on the mucous membrane of the left eyeball. Was prescribed treatment with chitosan. After a course of reception of chitosan 1 tablet (125 mg) 3 times a day for months nevus is completely resorbed. Scheduled preventive intake of vitamins (aevit and ascorbic acid) and say 2 times a year in spring and autumn in the month.

An example of treatment 3.

Patient K., 35 years old, I went to the doctor about nevus on the mucous membrane of the right eyeball. Was prescribed treatment with chitosan. After a course of reception of chitosan on 2 tablets (125 mg) 3 times a day for months nevus is completely resorbed. Scheduled preventive intake of vitamins (aevit and ascorbic acid) and say 2 times a year in spring and autumn in the month.

An example of treatment 4.

Patients., 51 years old, I went to the doctor about nevus on the mucous membrane of the right eyeball. Was prescribed treatment with chitosan. After a course of reception of chitosan 2 tablets (150 mg), 2 times a day for months nevus is completely resorbed. Scheduled preventive intake of vitamins (aevit and ascorbic acid) and say 2 times a year in spring and autumn in the month.

A method of treatment of nevus of the conjunctiva of the eye through the introduction of chitosan at a dose of 125-300 mg in the form of tablets or capsules 2-3 times a day for months.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to new condensed compounds (versions) or their pharmaceutically acceptable salts having inhibitory effect on HER2 and/or EGFR kinase, having the following formula, for example: or , where R1a is a hydrogen atom; R2a is a C1-8alkyl group, C2-8alkenyl group or C2-8alkynyl group, each of which is substituted with substitute(s), R3a is a hydrogen atom or C1-6alkyl group; or R1a and R2a are optionally bonded with formation or R2a and R3a are optionally bonded with formation of C2-4alkylene; Ba is a benzene ring optionally substituted with 1-4 substitutes selected from halogen and optionally halogenated C1-4alkyl; Ca is a phenyl group substituted with 1-5 substitutes selected from (i) halogen, (ii) optionally halogenated C1-4alkyl, (iii) hydroxy- C1-4alkyl, (iv) a 5-8-member heterocycle- C1-4alkyl, where the said 5-8-member heterocycle contains 1-3 heteroatoms selected from a nitrogen atom, oxygen atom and optionally oxidised sulphur atom, (v) optionally halogenated C1-4alkyloxy, (vi) cyano and (vii) carbamoyl, optionally substituted with C1-8alkyl, and, respectively, R2e is a C1-4alkyl group optionally substituted with -O-(CH2)n-OH, where n is an integer from 1 to 4; R3e is a hydrogen atom; Be is a benzene ring optionally substituted with a halogen; and Ce is a phenyl group optionally substituted with halogenated C1-4alkyl.

EFFECT: obtained new compounds can be used for treating cancer.

22 cl, 2 tbl, 280 ex

FIELD: chemistry.

SUBSTANCE: invention relates to new compounds of formula where L1 and L2 independently denote a bond, -S-, -NH- or unsubstituted C1-C5alkylene; A1 denotes a 6-member substituted aryl or unsubstituted heteroaryl; A2 denotes aryl or heteroaryl; R1 denotes halogen, -OR5, -NR6R7, -C(Z)R8, -S(O)wR9, -CN, -NO2, -S(O)2NH2, alkyl, aryl or heteroaryl; X1 denotes -C(R2)=, -C(R2)(R3)-, -N(R4)- or -O-; R2 and R3 independently denote hydrogen, -OR5 or alkyl; R4 denotes hydrogen or alkyl; Z denotes O or NH; w is integer from 0 to 2; R5 independently denotes hydrogen or alkyl; R6 and R7 independently denote hydrogen, -S(O)2R11 alkyl or heteroalkyl; R11 denotes hydrogen or alkyl; R8 independently denotes hydrogen, -NR14R15, -OR16, heteroalkyl or cycloalkyl; R14, R15 and R16 independently denote hydrogen, alkyl, cycloalkyl, heteroalkyl or heterocycloalkyl; R9 independently denotes hydrogen or alkyl; and where R6 and R7, R14 and R15 independently and optionally together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocycloalkyl. The invention also relates to a method of modulating protein kinase activity, as well as to use of compounds in paragraph 1 and a pharmaceutical composition based on the said compounds.

EFFECT: new compounds which can be useful in treating diseases mediated by kinase activity are obtained and described.

47 cl, 2 ex, 40 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in treating the patients with Non Hodgkin Lymphoma. That is ensured by administration of a combination containing an effective amount of CCI-779 and rituximab in the form of a dosage form with one or more neutral components added. The combination is introduced simultaneously, separately or consistently with the other agents.

EFFECT: method allows improving clinical effectiveness for the given pathology, including in the patients resistant to rituximab due to synergetic interactions of these preparations.

5 cl

Cancer treatment // 2389507

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to new drugs and preparations containing effective anticancer agent with anti-Hsp90 antibody.

EFFECT: invention improves clinical effectiveness in treating cancer and leukemia.

48 cl, 25 tbl

Cancer treatment // 2389507

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to new drugs and preparations containing effective anticancer agent with anti-Hsp90 antibody.

EFFECT: invention improves clinical effectiveness in treating cancer and leukemia.

48 cl, 25 tbl

FIELD: medicine.

SUBSTANCE: group of the inventions refers to medicine, namely to oncology and immunology and can be used for treating renal cell carcinoma or thymoma. The method is implemented as follows: Polypeptide containing amino acid precipitations 1-182 of a sequence SEQ ID NO:29 or precipitations 1-176 of a sequence SEQ ID NO: 159, is used for preparing a drug for treating renal cell carcinoma. Another aspect of the invention concerns application of polypeptide containing amino acid precipitations 1-176 of the sequence SEQ ID NO: 159 for preparing a drug for treating thymoma.

EFFECT: application of the inventions allows improving clinical effectiveness in said diseases due to tumour induction polypeptide reaction with reducing cytotoxic by-effects.

5 cl, 35 tbl, 6 dwg, 46 ex

FIELD: medicine.

SUBSTANCE: invention concerns biochemistry and medicine. There is offered therapeutic application of yessotoxins as inhibitors of human tumour cell growth. The mechanism of action of yessotoxin (YTX) is associated with activation of cell phosphodiesterases and respectively with decreasing the content of cyclic adenosine monophosphate in cytosol. This cytotoxic effect of YTX with respect to tumour cells can be applied as a strategy to develop preparation effective in treating tumour processes.

EFFECT: inhibition of human hepatocellular carcinoma cell growth following introduction of YTX.

3 cl, 1 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to application of transcript modifying agents to prevent the genetic grading of malignant cells required to resist cell damage and their survival in chemotherapy or radiotherapy. There is applied a pharmaceutical composition containing hydralazine and valproic acid or its salt, e.g. magnesium valproate, in a pharmaceutically acceptable carrier to assist in cancer treatment along with chemotherapy or radiotherapy.

EFFECT: invention provides synergetic effect in cancer treatment by conventional therapeutic agents.

5 cl, 5 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to drugs and concerns a pharmaceutical composition for percutaneous delivery of 4-hydroxy-tamoxsifen which contains 4-hydroxy-tamoxifen in an alcohol water solution where amount of spirit is 35-99.9 wt % of the composition weight, and about 45%-55%, about 46%-54%, about 47%-53%, about 48%-52%, about 49%-51% or about 50% of said 4-hydroxy-tamoxifen is found as an isomer Z and remained amount of said 4-hydroxy-tamoxifen is in the form of isomer E. There is also disclosed method for preparing a pharmaceutical composition for percutaneous delivery of 4-hydroxy-tamoxifen.

EFFECT: preparation of the pharmaceutical composition which contains an equilibrium ratio of isomers E and Z of 4-hydroxy-tamoxifen.

13 cl, 9 dwg, 4 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to four defined crystalline polymorphous forms of the monohydrate of a compound A having the following chemical composition:

.

Compound A. These four polymorphous forms, denoted here as forms I, II, III and IV, exhibit CXC chemokine receptor ligand activity.

EFFECT: invention relates to a pharmaceutical composition based on said compounds, to use thereof for treating different diseases and to methods for synthesising the said polymorphous forms.

58 cl, 2 tbl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to a method of treating ophthalmopathies. The method of treating an ophthalmopathy in a mammal by recovery from mammal's bone marrow of a population of haematopoietic stem cells of a negative lineage which includes precursor endotheliocytes, transfection of the prepared population with a gene which functionally codes a fragment of antiangiogenic protein T2 of human tryptophanyl-tRNA-synthetase, and the following introduction in a vitreous body of the population of transfected cells in amount sufficient for symptomatic relief. The method of transgene delivery in a retinal vasculature of the mammal by introducing in the mammal's vitreous body of the population of haematopoietic stem cells of the negative lineage including precursor endotheliocytes where the cells are transfected with the antiangiogenic fragment of protein T2 of human tryptophanyl-tRNA-synthetase.

EFFECT: method of treating the ophthalmopathy is novel and highly effective.

2 cl, 27 dwg, 2 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: for prevention and treatment of retinopathy in dismature infants with age of gestation from 29 weeks onto both child's eyes immediately after birth by lightproof bandage is applied. In addition, rectally daily during 3-4 months plasma is introduced, obtained from parent's blood, who was in conditions of darkness with opened eyes during 30-45 minutes.

EFFECT: invention ensures formation of morphologically and functionally full-fledged retina by removal of damaging light influence on retina and supply of child's organism with energetic and plastic material, obtained from parent's blood plasma.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: introductrion of Retinalamin medication in Tenon's space through single-channel catheter by 2.5 mg 2 times per day during 5 days is realised.

EFFECT: method allows to ensure longer effect from application of medication, increase visual functions, reduce amount of side effects.

2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely ophthalmology, and can be used in preparing a material for glaucoma surgery in adults and children. There is offered method for preparing the material for glaucoma surgery that involves collagen production and preparation with glycosaminoglycans with the raw materials for collagen production being an animal and/or human connective tissue. Concentration of the prepared collagen in a solution is 0.5-6.0 wt % to be heated to temperature 35-45C, cooled to temperature 0C to 18C to gelation. The gel is exposed to ionising radiation, moulded and sterilised. Collagen preparation with glycosaminoglycans precedes cooling or follows radiation in the ratio of glycosaminoglycans and collagen 1:(4-8.2) weight units, respectively.

EFFECT: invention allows improving efficiency of glaucoma surgery ensured by ability of the prepared material to maintain volume of a filtering zone, to provide the graduated filtration, to prevent formation fibrosis within implantation region.

5 cl, 13 ex

FIELD: medicine.

SUBSTANCE: there is offered application of group of survival-improving polypeptide cone cells originated from rod cells and designated as RDCF, and also coding molecules of nucleic acid to prepare medicines, particularly pharmaceutical compositions used to treat retinal dystrophy. Methods for preparing RDCF by recombinant DNA technologies, and required aids, as well as preparation of antibodies distinguishing said polypeptides are described.

EFFECT: improved clinical effectivenesses.

12 cl, 19 dwg, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound or its salt of formula 1: , where A, E, D, R0, R1-R4 and a assume values given in the formula of invention. The invention also relates to an antioxidant medicinal agent.

EFFECT: effectiveness during treatment of ischemic diseases of organs, during treatment of diseases caused by oxidation cell disorders and when inhibiting disorders of the retina.

4 cl, 1 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves daily application of silver water with silver concentration 25 mg/l and more. Silver water is administered once a day by bath magnetophoresis. The magnetic induction 10-15 mT is used. Procedure duration is 10 minutes for treatment course of 5-6 procedures.

EFFECT: method improves clinical effectiveness for infectious keratitis and conjunctivitis.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: inventions refers to medicine, namely to ophthalmology, and aims at treating the inflammatory exudative postoperative reactions following implantation of an intraocular lens. The conventional therapy is combined with intramuscular introduction of Galavit, the 1 and 2 day 0.2 g, and starting from the 4 day 0.1 g, 10 injections every second day.

EFFECT: method allows improving clinical effectiveness ensured by short-term reduction of the inflammatory reaction, improved visual acuity, shorter staying in hospital.

2 ex

FIELD: medicine.

SUBSTANCE: in early after-burn period, with underlying antiinflammatory, antibacterial and trophic treatment, additionally alprostadil in single dosing 40 mcg dissolved in 200 mg of physiologic saline is introduced intravenously drop-by-drop within 2 hours.

EFFECT: method allows for conventional and effective treatment of burns of the conjunctiva ensured by effect of alprostadil on pathogenic links of the burn disease.

3 ex

FIELD: medicine.

SUBSTANCE: composition is applied for treatment of dry-eye syndrome. The composition for treatment of dry-eye syndrome contains omega-3 fatty acids and omega-6 fatty acids, zinc compounds, preferentially in the form of zinc sulphate. It can be applied as a dietary supplement to the balanced diet.

EFFECT: effective treatment of dry-eye syndrome.

14 cl, 12 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology. The method for prevention of adhesive process in peritoneal cavity in obstetric-gynaecologic surgeries involving administration of chitosan compounds and differing that the compound is applied in layer-by-layer suturing of an operative wound in preperitoneal and skin structure of anterior abdominal wall. The compound represents a sponge measured 601004 mm to 2401804 mm and containing 2% collagen acetate, 2% chitosan ascorbate of degree of deacetylation 95% and more, molecular weight 100 to 700 kDa, ascorbic acid - 1.8 g/g of dry chitosan, chondroitin-sulphuric acid - 5-100 mg/g of dry chitosan, hyaluronic acid - 10-100 mg/g of dry chitosan, heparin - 2.5-5 mg/g of dry chitosan and bovine serum growth factor "Adgelon" - 11-220 mkg/g of dry chitosan.

EFFECT: method improves effectiveness of prevention of postoperative adhesive process in small pelvis in women, prevents development of exudative processes in the operative wound tissues and accelerates the healing.

2 tbl, 1 ex

Up!